论文部分内容阅读
1993年2月,英国药品警戒当前问题会议讨论了SmithKline Beecham(SB)生产的抗生素奥格门汀(augmentin,阿莫西林-克拉维酸复方制剂)导致肝功能异常以及喹诺酮类药物的不良反应等问题,并公布讨论情况。奥格门汀中的克拉维酸可导致胆汁郁积反应,因为几乎未收到只用阿莫西林发生类似反应的报告。当局已收到138例由奥格门汀引起肝胆疾病的报告,其中3例死亡。此反应占怀疑与该复方有关的不良药物反应(ADRs)报告总数的12％。发生上述ADRs的患者中年龄60岁以上的占50％,其中70％的患者在停用该抗生素(甚至达6周)后才出现上述反
In February 1993, the current issue of drug alerting in the UK discussed the adverse effects of augmentin (amoxicillin-clavulanate) produced by SmithKline Beecham (SB) on hepatic dysfunction and quinolones Issue and publish the discussion. Clavulanic acid in augmentin results in a cholestatic response because few reports of similar reactions with only amoxicillin have been received. Authorities have received 138 reports of hepatobiliary diseases caused by augmentin, of which 3 were fatal. This response represents 12% of the total number of adverse drug reaction (ADRs) reports suspected of being associated with the compound. Over 50% of patients over 60 years of age develop ADRs, 70% of whom discontinue the antibiotic (up to 6 weeks)